| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Organogenesis Holdings Inc (NASDAQ: ORGO)
ORGO Technical Analysis
5
| As on 9th Jun 2023 ORGO STOCK Price closed @ 4.02 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 5.81 & Strong Sell for SHORT-TERM with Stoploss of 8.10 we also expect STOCK to react on Following IMPORTANT LEVELS. |
ORGOSTOCK Price
| Open | 4.18 | Change | Price | % |
| High | 4.20 | 1 Day | -0.11 | -2.66 |
| Low | 4.00 | 1 Week | 0.25 | 6.63 |
| Close | 4.02 | 1 Month | 2.06 | 105.10 |
| Volume | 872800 | 1 Year | -5.47 | -57.64 |
| 52 Week High 10.20 | 52 Week Low 1.89 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| ORGO Daily Charts |
ORGO Intraday Charts |
Whats New @ Bazaartrend |
ORGO Free Analysis |
|
|
ORGO Important Levels Intraday
| RESISTANCE | 4.41 |
| RESISTANCE | 4.28 |
| RESISTANCE | 4.21 |
| RESISTANCE | 4.13 |
| SUPPORT | 3.91 |
| SUPPORT | 3.83 |
| SUPPORT | 3.76 |
| SUPPORT | 3.63 |
ORGO Forecast May 2024
| 4th UP Forecast | 8.7 |
| 3rd UP Forecast | 7.2 |
| 2nd UP Forecast | 6.27 |
| 1st UP Forecast | 5.34 |
| 1st DOWN Forecast | 2.7 |
| 2nd DOWN Forecast | 1.77 |
| 3rd DOWN Forecast | 0.84 |
| 4th DOWN Forecast | -0.66 |
ORGO Weekly Forecast
| 4th UP Forecast | 6.66 |
| 3rd UP Forecast | 5.81 |
| 2nd UP Forecast | 5.29 |
| 1st UP Forecast | 4.77 |
| 1st DOWN Forecast | 3.27 |
| 2nd DOWN Forecast | 2.75 |
| 3rd DOWN Forecast | 2.23 |
| 4th DOWN Forecast | 1.38 |
ORGO Forecast2024
| 4th UP Forecast | 20.57 |
| 3rd UP Forecast | 15.26 |
| 2nd UP Forecast | 11.98 |
| 1st UP Forecast | 8.7 |
| 1st DOWN Forecast | -0.66 |
| 2nd DOWN Forecast | -3.94 |
| 3rd DOWN Forecast | -7.22 |
| 4th DOWN Forecast | -12.53 |
Organogenesis Holdings Inc ( NASDAQ USA Symbol : ORGO )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
ORGO Business Profile
Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic allograft wound covering and surgical barrier for application in the care of chronic and acute wounds or surgical implantation in spine, orthopedic, and sports medicine applications; Apligraf, a bioengineered bi-layered skin substitute for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft, a dermal substitute for the treatment of DFUs; NuShield, a dehydrated placental tissue wound covering and surgical barrier applied to the target tissue to support native healing; and PuraPly Antimicrobial, an antimicrobial barrier skin substitute to treat chronic and acute wounds. Its surgical and sports medicine products comprise NuCel, a surgically implanted allograft used primarily in spinal and orthopedic surgical applications; ReNu, a cryopreserved suspension used to support healing of soft tissues; and FiberOS and OCMP used as a bone void filler primarily in orthopedic and neurosurgical applications. The company's pipeline products include PuraPly XT and PuraPly MZ to treat chronic, acute, and open wounds; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; Novachor, a chorionic membrane wound covering; TransCyte, a bioengineered tissue for the treatment of partial thickness burns; and Gintuit, a bioengineered bi-layered living cellular tissue for the treatment of mucogingival conditions in adults. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales force and independent agencies. The company was founded in 1985 and is headquartered in Canton, Massachusetts. Address: 85 Dan Road, Canton, MA, United States, 02021
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service